Protocol Page


	Study ID (Protocol Number)
	CA209-039


	STUDY LOCATIONS*
	Abramson Cancer Center Of The University Of Pennsylvania Philadelphia, PA 19104 Recruiting	Fox Chase Cancer Center Philadelphia, PA 19111 Recruiting
	Dana-Farber Cancer Institute Boston, MA 02215 Recruiting	Holy Cross Hospital-Bienes Cancer Center Fort Lauderdale, FL 33308 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy
	STUDY OVERVIEW
	The purpose of this study is to determine the side effects of treatment with the monoclonal antibody anti-PD-1 (BMS-936558) in subjects with relapsed/refractory hematologic malignancy and the dose that should be recommended for use in future studies.

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.